Fundraising Fox

Oligomerix

White Plains, US · Delaware corporation

Biotech

Founders & leadership

ED
Eliot DavidowitzCo-founder
JM
James MoeCo-founder
WE
William ErhardtExecutive
RF
Robert FoersterExecutive
JP
Jack PasiniExecutive

Board

DD
David DantzkerBoard director
DD
Douglas DurandBoard director
JB
Jeffrey BluesteinBoard director
VM
Victor MicatiBoard director

Reported raises · per SEC filings

Form D private placements

$2.9M disclosed across 3 of 4 rounds · 2012–2024

▶$75KraisedDec 2024 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Douglas DurandDirector
  • William ErhardtExecutive Officer, Director
  • Robert FoersterExecutive Officer, Director
  • Jeffrey BluesteinDirector
  • Eliot DavidowitzExecutive Officer, Director
  • James MoeExecutive Officer, Director
  • David DantzkerDirector
  • Jack PasiniExecutive Officer, Director
Offering amount
$650K
Amount sold
$75K
First sale
Nov 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.4MraisedMar 2022 · 12 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeffrey BluesteinDirector
  • Robert ForesterExecutive Officer
  • Douglas DurandDirector
  • Jack PasiniDirector
  • James MoeExecutive Officer, Director
  • David DantzkerDirector
  • William ErhardtDirector
  • Victor MicatiDirector
  • Eliot DavidowitzDirector
Offering amount
$3.5M
Amount sold
$2.4M
Proceeds to insiders
$650K
First sale
Mar 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$400KraisedApr 2015 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeffrey BluesteinDirector
  • Douglas DurandDirector
  • Jack PasiniDirector
  • James MoeExecutive Officer, Director
  • David DantzkerDirector
  • Victor MicatiDirector
Offering amount
$3M
Amount sold
$400K
Proceeds to insiders
$200K
First sale
Apr 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.7MofferedMar 2012 · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • David DantzkerDirector
  • Douglas DurandDirector
  • James MoeExecutive Officer, Director
  • Jack PasiniDirector
  • Victor MicatiDirector
Offering amount
$2.7M
Minimum investment
$25K
Proceeds to insiders
$94.5K
Incorporated
Corporation, Delaware
Federal exemptions
06
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

NIH awards $3.35M to Oligomerix for development of tau-targeting AD therapyhealio.com · Aug 2022Oligomerix Awarded $3.35M from NIH to Support Clinical Development of Tau-Targeting Alzheimer’s Disease Therapy - BioSpacebiospace.com · Aug 2022Oligomerix Closes $2.7M Series B Extension - FinSMEsfinsmes.com · Jun 2022Oligomerix Announces Series B Extension Raise of $2.7 Million to Support Phase 1 Clinical Development - BioSpacebiospace.com · Jun 2022Oligomerix, Inc. Completes $2 Million Series A Financingprnewswire.com · Apr 2012Oligomerix Completes $2M in Series A Financing - FinSMEsfinsmes.com · Apr 2012

Frequently asked questions

Who founded Oligomerix?
Oligomerix was founded by Eliot Davidowitz, James Moe.
How much funding has Oligomerix raised?
Oligomerix has disclosed $2.9M raised across 3 of its 4 known rounds.
Where is Oligomerix headquartered?
Oligomerix is headquartered in White Plains, US.